Evidence Hub

Use of Multiplex Molecular Panels to Diagnose Urinary Tract Infection in Older Adults

Kelly M. Hatfield, S. Kabbani, Isaac See, Dustin W. Currie, Christine Kim, Kara Jacobs Slifka, S. Magill, Lauri A. Hicks et al.

JAMA Network Open, 2024

7 citations

Abstract

Key Points Question How frequently are multiplex molecular syndromic panels used to diagnose urinary tract infection (UTI) among older Medicare beneficiaries? Findings In this cohort study of older adults, Medicare fee-for-service claims for multiplex testing with a primary diagnosis of UTI increased from 2 to 148 claims per 10 000 beneficiaries annually between 2016 and 2023. Meaning These findings suggest that claims for costly multiplex molecular testing for UTI are frequent among Medicare beneficiaries, including nursing home residents, despite a lack of clinical evidence supporting their value.

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free